Leib played leading role in advocating for 2008 Genetic Information Nondiscrimination Act, has championed personalized medicine for more than a decade
WASHINGTON (January 5, 2017)
The Personalized Medicine Coalition (PMC) is pleased to announce that Jennifer Leib, Senior Vice President, CRD Associates, who was a leading advocate for the 2008 Genetic Information Nondiscrimination Act (GINA) and has been championing personalized medicine for more than a decade, will serve as lead principal on a CRD contract to enhance the Coalition’s policy activities and help select its next vice president for public policy.
Leib and CRD Associates will help increase the impact of the Coalition’s policy programs in 2017, which include a Congressional briefing and the 13th Annual State of Personalized Medicine Luncheon Address at the National Press Club on May 2. Lyle Dennis, CRD Partner, and Megan Anderson Brooks, Ph.D., CRD Vice President, will also assist with the scope of work.
Leib began her career as a genetic counselor at the National Institutes of Health before being selected for the prestigious National Human Genome Research Institute (NHGRI)/American Society of Human Genetics’ Genetics and Public Policy Fellowship in 2003. She worked directly in the office of then NHGRI Director Francis S. Collins, M.D., Ph.D., and also worked on the late Senator Edward M. Kennedy’s Health, Education, Labor and Pensions Committee staff for two years. She began working with PMC during the Coalition’s first year, while serving as director of government relations and public policy for Affymetrix, a founding PMC member. It was in that capacity that Leib played a leading advocacy role for GINA and served on the Executive Committee of the Coalition for Genetic Fairness, which also helped inform the GINA regulatory process.
She joined CRD Associates in 2009, after CRD acquired HealthFutures, a government relations and public policy firm that Leib co-founded with former PMC board member Robert Wells. In this capacity, she advises clients on policy issues of interest to PMC members, including oversight of diagnostics, reimbursement of personalized medicine products and genetic privacy.
Leib said she looks forward to working with the Coalition to help create a more favorable policy environment for personalized medicine in the new Congress and new administration, which she believes will be essential to furthering progress in the field.
"PMC’s education and advocacy mission is critical to the success of personalized medicine, which can improve patients’ lives,” Leib said. "On behalf of CRD, I look forward to deepening our relationship with the organization.”
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.